Key result
The recombinant rotavirus vaccine antigens P2-VP8-P[4] and P2-VP8-P[6] displayed similar physical stability profiles, while P2-VP8-P[8] was relatively more stable to pH and temperature stresses.
Why the study?
Live attenuated rotavirus vaccines show substantially lower efficacy in low- to middle-income settings, leading to interest in alternative vaccine candidates.
The study establishes key structural attributes and stability profiles of three recombinant rotavirus antigens, informing future vaccine formulation development.
P2-VP8-P[8] stability edge informs antigen selection; leaves open human immunogenicity and efficacy trials.
Although live attenuated Rotavirus (RV) vaccines are available globally to provide protection against enteric RV disease, efficacy is substantially lower in low- to middle-income settings leading to interest in alternative vaccines. One promising candidate is a trivalent nonreplicating RV vaccine, comprising 3 truncated RV VP8 subunit proteins fused to the P2 CD4+ epitope from tetanus toxin (P2-VP8-P[4/6/8]). A wide variety of analytical techniques were used to compare the physicochemical properties of these 3 recombinant fusion proteins. Various environmental stresses were used to evaluate antigen stability and elucidate degradation pathways. P2-VP8-P[4] and P2-VP8-P[6] displayed similar physical stability profiles as function of pH and temperature while P2-VP8-P[8] was relatively more stable. Forced degradation studies revealed similar chemical stability profiles with Met1 most susceptible to oxidation, the single Cys residue (at position 173/172) forming intermolecular disulfide bonds (P2-VP8-P[6] was most susceptible), and Asn7 undergoing the highest levels of deamidation. These results are visualized in a structural model of the nonreplicating RV antigens. The establishment of key structural attributes of each antigen, along with corresponding stability-indicating methods, have been applied to vaccine formulation development efforts (see companion paper), and will be utilized in future analytical comparability assessments.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2019) studied Rotavirus disease. Trivalent nonreplicating RV vaccine candidate (P2-VP8-P[4/6/8]) was evaluated on Physicochemical properties and stability profiles. The recombinant rotavirus vaccine antigens P2-VP8-P[4] and P2-VP8-P[6] displayed similar physical stability profiles, while P2-VP8-P[8] was relatively more stable to pH and temperature stresses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: